Acylation stimulating protein stimulates insulin secretion

B. Ahrén, Peter J Havel, G. Pacini, K. Cianflone

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat. We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 μmol/l. The effect was glucose-dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose. Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in response to depolarization by 20 mmol/l of KCI. ASP-induced insulin secretion was completely abolished by competitive inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca2+-ATPase in the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (> 5 μmol/l) also augmented glucose-stimulated insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (S1) or glucose effectiveness (SG). We conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo results in augmented glucose disposal.

Original languageEnglish (US)
Pages (from-to)1037-1043
Number of pages7
JournalInternational Journal of Obesity
Volume27
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

acylation
protein secretion
insulin secretion
Insulin
Glucose
glucose
proteins
hormones
protein kinase C
Hormones
des-Arg-(77)-complement C3a
Inbred C57BL Mouse
Protein Kinase C
phosphorylation
Phosphorylation
glyceraldehyde
Glyceraldehyde
glucokinase
calcium channel blockers
Glucokinase

Keywords

  • Acylation stimulating protein
  • ASP
  • In vivo
  • INS cells
  • Insulin secretion
  • Insulin sensitivity
  • Mice

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Acylation stimulating protein stimulates insulin secretion. / Ahrén, B.; Havel, Peter J; Pacini, G.; Cianflone, K.

In: International Journal of Obesity, Vol. 27, No. 9, 01.09.2003, p. 1037-1043.

Research output: Contribution to journalArticle

Ahrén, B. ; Havel, Peter J ; Pacini, G. ; Cianflone, K. / Acylation stimulating protein stimulates insulin secretion. In: International Journal of Obesity. 2003 ; Vol. 27, No. 9. pp. 1037-1043.
@article{ed25c5a4545d4d59ad224a65b55600ac,
title = "Acylation stimulating protein stimulates insulin secretion",
abstract = "Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat. We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 μmol/l. The effect was glucose-dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose. Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in response to depolarization by 20 mmol/l of KCI. ASP-induced insulin secretion was completely abolished by competitive inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca2+-ATPase in the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (> 5 μmol/l) also augmented glucose-stimulated insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (S1) or glucose effectiveness (SG). We conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo results in augmented glucose disposal.",
keywords = "Acylation stimulating protein, ASP, In vivo, INS cells, Insulin secretion, Insulin sensitivity, Mice",
author = "B. Ahr{\'e}n and Havel, {Peter J} and G. Pacini and K. Cianflone",
year = "2003",
month = "9",
day = "1",
doi = "10.1038/sj.ijo.0802369",
language = "English (US)",
volume = "27",
pages = "1037--1043",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Acylation stimulating protein stimulates insulin secretion

AU - Ahrén, B.

AU - Havel, Peter J

AU - Pacini, G.

AU - Cianflone, K.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat. We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 μmol/l. The effect was glucose-dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose. Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in response to depolarization by 20 mmol/l of KCI. ASP-induced insulin secretion was completely abolished by competitive inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca2+-ATPase in the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (> 5 μmol/l) also augmented glucose-stimulated insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (S1) or glucose effectiveness (SG). We conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo results in augmented glucose disposal.

AB - Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat. We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 μmol/l. The effect was glucose-dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose. Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in response to depolarization by 20 mmol/l of KCI. ASP-induced insulin secretion was completely abolished by competitive inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca2+-ATPase in the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (> 5 μmol/l) also augmented glucose-stimulated insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (S1) or glucose effectiveness (SG). We conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo results in augmented glucose disposal.

KW - Acylation stimulating protein

KW - ASP

KW - In vivo

KW - INS cells

KW - Insulin secretion

KW - Insulin sensitivity

KW - Mice

UR - http://www.scopus.com/inward/record.url?scp=0041818412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041818412&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802369

DO - 10.1038/sj.ijo.0802369

M3 - Article

C2 - 12917708

AN - SCOPUS:0041818412

VL - 27

SP - 1037

EP - 1043

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 9

ER -